Translational neurodegeneration

In the field of translational neurodegeneration, we combine patient-related research with research into genetic, molecular and pathophysiological mechanisms that are at the forefront of neurodegenerative Parkinson's syndromes. Neurodegenerative Parkinson's syndromes include diseases in which there is pathological aggregation of alpha-synuclein (idiopathic Parkinson's syndrome, dementia with Lewy bodies, multisystem atrophy) and diseases in which there is pathological aggregation of the tau protein (progressive supranuclear palsy, corticobasal degeneration).

We are interested in genetic changes and biological mechanisms that lead to the aggregation of alpha-synuclein and tau, the causes of neuronal cell death and the development of ways to protect neurons from destruction.

Our research focuses on genetic investigation methods, protein biochemical approaches and cell models of the various diseases. This enables us to investigate disease mechanisms in a model-like manner and test therapeutic approaches with substances that could potentially be used as drugs.

Based on clinical and experimental observations, we aim to develop and refine pathophysiological disease concepts that allow us to predict promising therapeutic targets and ultimately test these in clinical trials.